Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Issued Date
2023-01-13
Resource Type
eISSN
15376591
Scopus ID
2-s2.0-85145910494
Pubmed ID
36196614
Journal Title
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume
76
Issue
2
Start Page
201
End Page
209
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Vol.76 No.2 (2023) , 201-209
Suggested Citation
Fidler S., Fox J., Tipoe T., Longet S., Tipton T., Abeywickrema M., Adele S., Alagaratnam J., Ali M., Aley P.K., Aslam S., Balasubramanian A., Bara A., Bawa T., Brown A., Brown H., Cappuccini F., Davies S., Fowler J., Godfrey L., Goodman A.L., Hilario K., Hackstein C.P., Mathew M., Mujadidi Y.F., Packham A., Petersen C., Plested E., Pollock K.M., Ramasamy M.N., Robinson H., Robinson N., Rongkard P., Sanders H., Serafimova T., Spence N., Waters A., Woods D., Zacharopoulou P., Barnes E., Dunachie S., Goulder P., Klenerman P., Winston A., Hill A.V.S., Gilbert S.C., Carroll M., Pollard A.J., Lambe T., Ogbe A., Frater J. Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Vol.76 No.2 (2023) , 201-209. 209. doi:10.1093/cid/ciac796 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82462
Title
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Author(s)
Fidler S.
Fox J.
Tipoe T.
Longet S.
Tipton T.
Abeywickrema M.
Adele S.
Alagaratnam J.
Ali M.
Aley P.K.
Aslam S.
Balasubramanian A.
Bara A.
Bawa T.
Brown A.
Brown H.
Cappuccini F.
Davies S.
Fowler J.
Godfrey L.
Goodman A.L.
Hilario K.
Hackstein C.P.
Mathew M.
Mujadidi Y.F.
Packham A.
Petersen C.
Plested E.
Pollock K.M.
Ramasamy M.N.
Robinson H.
Robinson N.
Rongkard P.
Sanders H.
Serafimova T.
Spence N.
Waters A.
Woods D.
Zacharopoulou P.
Barnes E.
Dunachie S.
Goulder P.
Klenerman P.
Winston A.
Hill A.V.S.
Gilbert S.C.
Carroll M.
Pollard A.J.
Lambe T.
Ogbe A.
Frater J.
Fox J.
Tipoe T.
Longet S.
Tipton T.
Abeywickrema M.
Adele S.
Alagaratnam J.
Ali M.
Aley P.K.
Aslam S.
Balasubramanian A.
Bara A.
Bawa T.
Brown A.
Brown H.
Cappuccini F.
Davies S.
Fowler J.
Godfrey L.
Goodman A.L.
Hilario K.
Hackstein C.P.
Mathew M.
Mujadidi Y.F.
Packham A.
Petersen C.
Plested E.
Pollock K.M.
Ramasamy M.N.
Robinson H.
Robinson N.
Rongkard P.
Sanders H.
Serafimova T.
Spence N.
Waters A.
Woods D.
Zacharopoulou P.
Barnes E.
Dunachie S.
Goulder P.
Klenerman P.
Winston A.
Hill A.V.S.
Gilbert S.C.
Carroll M.
Pollard A.J.
Lambe T.
Ogbe A.
Frater J.
Author's Affiliation
NIHR Imperial Biomedical Research Centre
Chinese Academy of Medical Sciences Oxford Institute
NIHR Oxford Biomedical Research Centre
NIHR Guy's and St Thomas' Biomedical Research Centre
Oxford University Hospitals NHS Foundation Trust
Public Health England
St Mary's Hospital
University College London
Imperial College Faculty of Medicine
Mahidol University
Nuffield Department of Medicine
Guy's and St Thomas' NHS Foundation Trust
University of Oxford Medical Sciences Division
Chinese Academy of Medical Sciences Oxford Institute
NIHR Oxford Biomedical Research Centre
NIHR Guy's and St Thomas' Biomedical Research Centre
Oxford University Hospitals NHS Foundation Trust
Public Health England
St Mary's Hospital
University College London
Imperial College Faculty of Medicine
Mahidol University
Nuffield Department of Medicine
Guy's and St Thomas' NHS Foundation Trust
University of Oxford Medical Sciences Division
Other Contributor(s)
Abstract
BACKGROUND: People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are few data on longer term responses and the impact of a booster dose. METHODS: Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed 12 months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µL. Immune responses to the ancestral strain and variants of concern were measured by anti-spike immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, activation induced marker (AIM) assay, and T-cell proliferation. FINDINGS: In total, 54 participants received 2 doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) 1 year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titers (MSD), ACE-2 inhibition, and IgG ELISA results were significantly higher compared to Day 182 titers (P < .0001 for all 3). SARS-CoV-2 specific CD4+ T-cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4+ and CD8+ T-cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron. CONCLUSIONS: In PWH receiving a third vaccine dose, there were significant increases in B- and T-cell immunity, including to known variants of concern (VOCs).